OncoCyte Corporation
Index- P/E- EPS (ttm)-0.77 Insider Own0.50% Shs Outstand92.24M Perf Week-6.88%
Market Cap103.16M Forward P/E- EPS next Y-0.42 Insider Trans- Shs Float48.53M Perf Month-14.68%
Income-70.50M PEG- EPS next Q-0.12 Inst Own46.40% Short Float10.07% Perf Quarter-36.93%
Sales8.00M P/S12.89 EPS this Y-57.70% Inst Trans-1.98% Short Ratio7.60 Perf Half Y-61.66%
Book/sh0.62 P/B1.40 EPS next Y8.50% ROA-43.30% Target Price3.15 Perf Year-85.49%
Cash/sh0.18 P/C4.91 EPS next 5Y- ROE-86.90% 52W Range0.84 - 6.25 Perf YTD-59.89%
Dividend- P/FCF- EPS past 5Y-11.40% ROI-95.70% 52W High-86.08% Beta1.79
Dividend %- Quick Ratio1.80 Sales past 5Y- Gross Margin-5.30% 52W Low4.10% ATR0.10
Employees110 Current Ratio1.80 Sales Q/Q27.30% Oper. Margin- RSI (14)34.87 Volatility12.58% 10.24%
OptionableYes Debt/Eq0.02 EPS Q/Q-133.80% Profit Margin- Rel Volume1.13 Prev Close0.91
ShortableYes LT Debt/Eq0.00 EarningsMay 11 AMC Payout- Avg Volume643.12K Price0.87
Recom1.90 SMA20-18.28% SMA50-21.57% SMA200-57.31% Volume728,840 Change-4.53%
May-24-22Downgrade Stephens Overweight → Equal-Weight
Mar-14-22Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Jan-07-22Initiated Stephens Overweight $3.10
Jan-06-22Resumed Piper Sandler Overweight $3.10
Mar-17-21Resumed Needham Buy $8
Jan-07-21Upgrade The Benchmark Company Speculative Buy → Buy $6
Dec-16-20Upgrade Piper Sandler Neutral → Overweight $2 → $4
Nov-30-20Initiated BTIG Research Buy $5
Nov-10-20Initiated KeyBanc Capital Markets Overweight $5
Jul-30-20Reiterated The Benchmark Company Speculative Buy $7 → $6
Jul-01-20Downgrade Piper Sandler Overweight → Neutral
Jun-30-20Downgrade Chardan Capital Markets Buy → Neutral $2
Jun-02-20Initiated Needham Buy $4
Feb-13-19Initiated Piper Jaffray Overweight $6
Jan-29-19Upgrade Janney Neutral → Buy
Dec-19-18Resumed Lake Street Buy
Jun-22-22 08:00AM  
Jun-15-22 07:15AM  
May-26-22 05:00PM  
May-11-22 04:05PM  
May-05-22 08:00AM  
Apr-28-22 04:01PM  
Apr-27-22 04:30PM  
Apr-22-22 09:26AM  
Apr-13-22 10:01PM  
Apr-11-22 08:00AM  
Mar-28-22 08:00AM  
Mar-10-22 04:05PM  
Mar-01-22 04:05PM  
Feb-21-22 07:26AM  
Feb-10-22 08:00AM  
Jan-18-22 04:05PM  
Jan-06-22 09:43AM  
Jan-04-22 08:00AM  
Dec-09-21 06:00PM  
Dec-08-21 08:00AM  
Dec-06-21 08:00AM  
Dec-02-21 08:00AM  
Nov-22-21 06:14AM  
Nov-09-21 04:05PM  
Nov-04-21 08:00AM  
Nov-02-21 03:02PM  
Oct-27-21 08:00AM  
Oct-26-21 04:05PM  
Oct-08-21 09:46AM  
Oct-07-21 08:00AM  
Sep-30-21 08:00AM  
Sep-20-21 11:35AM  
Sep-16-21 08:00AM  
Sep-13-21 08:00AM  
Sep-07-21 04:05PM  
Aug-23-21 09:13AM  
Aug-18-21 08:49AM  
Aug-17-21 08:00AM  
Aug-10-21 04:01PM  
Aug-09-21 08:00AM  
Aug-03-21 03:00PM  
Jul-27-21 10:35AM  
Jul-08-21 05:34AM  
Jun-22-21 08:00AM  
Jun-15-21 08:03AM  
Jun-03-21 08:00AM  
Jun-01-21 08:00AM  
May-24-21 05:26AM  
May-17-21 04:01PM  
May-06-21 08:00AM  
May-04-21 04:01PM  
Apr-28-21 04:31PM  
Apr-19-21 08:00AM  
Apr-14-21 09:02AM  
Apr-10-21 01:31PM  
Apr-06-21 04:05PM  
Mar-23-21 01:44AM  
Mar-16-21 04:01PM  
Mar-15-21 08:00AM  
Mar-09-21 08:00AM  
Mar-04-21 08:00AM  
Mar-03-21 04:01PM  
Feb-25-21 08:00AM  
Feb-23-21 04:05PM  
Feb-16-21 04:05PM  
Feb-09-21 04:05PM  
Feb-05-21 06:06PM  
Feb-04-21 04:05PM  
Feb-02-21 09:35AM  
Jan-29-21 08:30PM  
Jan-28-21 08:00AM  
Jan-20-21 04:08PM  
Jan-12-21 06:21PM  
Dec-17-20 08:50AM  
Dec-15-20 10:48AM  
Dec-07-20 04:05PM  
Nov-30-20 05:38PM  
Nov-18-20 04:05PM  
Nov-17-20 11:55PM  
Nov-16-20 05:49AM  
Nov-12-20 04:05PM  
Nov-09-20 04:05PM  
Nov-05-20 11:23AM  
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PURA VIDA INVESTMENTS, LLC10% OwnerJun 24Sale1.0399,386102,6357,427,202Jun 28 07:48 PM
Yu LiVP Cntrllr/Prncpl Acctng OffcrMay 18Option Exercise0.0025,000025,000May 19 05:58 PM
Yu LiVP Cntrllr/Prncpl Acctng OffcrMay 18Sale1.148,1289,26616,872May 19 05:58 PM
PURA VIDA INVESTMENTS, LLC10% OwnerApr 14Buy1.335,931,7077,887,8508,532,663Apr 18 09:55 PM
BROADWOOD PARTNERS, L.P.10% OwnerApr 14Buy1.336,003,7528,000,00023,353,697Apr 15 06:13 PM
Ross Douglas T.Chief Scientific OfficerMar 25Buy1.4015,00021,00020,317Mar 28 08:00 PM
Paulsen GiselaChief Operating OfficerMar 17Buy1.2016,50019,76716,500Mar 17 09:27 PM
Redmond Cavan M.DirectorMar 16Buy1.1940,00047,560110,863Mar 16 09:08 PM
ANDREWS RONALD ASBURYChief Executive OfficerMar 16Buy1.2850,00064,150293,212Mar 17 09:26 PM
Levine Mitchell SChief Financial OfficerMar 15Buy1.1725,00029,15087,080Mar 15 04:19 PM
ANDREWS RONALD ASBURYChief Executive OfficerJul 01Option Exercise0.0065,0000259,046Jul 02 09:32 PM